Redefining Durability in Wet AMD: Insights from the SOL‑1 Superiority Trial

Host: Priya Vakharia, MD Guest: Andrew Moshfeghi, MD The SOL-1 Phase 3 superiority trial compared the efficacy and safety of the investigational product OTX-TKI (axitinib intravitreal hydrogel) with aflibercept 2 mg. The primary endpoint was proportion of subjects who maintained visual acuity, defined as <15 Early Treatment Diabetic Retinopathy Study letters of best-corrected visual acuity loss…